YDESNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as YDESW

YD Bio Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026

$6.12+0.20 (+3.38%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

YD Bio Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	0.60	0.51	0.35
Cost of Revenue	0.43	0.36	0.20
Gross Profit	0.17	0.16	0.15
Research & Development	1.60	0.49	–
Selling, General & Admin	3.83	1.13	0.16
Selling & Marketing	0.17	0.00	0.01
General & Administrative	3.66	1.12	0.15
Operating Expenses	5.44	1.62	0.16
Operating Income	-5.27	-1.46	-0.01
Interest Expense	–	0.00	0.00
Interest & Investment Income	0.08	0.01	0.00
Other Non-Operating Income	-3.04	0.08	0.03
Gain (Loss) on Sale of Assets	0.00	–	0.00
Pretax Income	-8.31	-1.39	0.02
Income Tax Expense	0.00	0.03	0.00
Net Income	-8.31	-1.41	0.01
EPS (Basic)(per share)	-0.12	-0.02	0.00
EPS (Diluted)(per share)	-0.12	-0.02	0.00
Shares Outstanding (Basic, Weighted)(shares)	67	65	65
Shares Outstanding (Diluted, Weighted)(shares)	67	65	65

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 28.1%
Operating margin: -883.3%
Net margin: -1392.6%
Return on equity, FY2025: -445.1%

Financial strength

Current ratio: 5.23
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 249.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –